Research programme: apolipoprotein B100 gene therapy - uniQure

Drug Profile

Research programme: apolipoprotein B100 gene therapy - uniQure

Alternative Names: ApoB100 gene therapy - uniQure

Latest Information Update: 16 Jul 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amsterdam Molecular Therapeutics
  • Class Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hypercholesterolaemia

Most Recent Events

  • 16 Jul 2012 Discontinued - Preclinical for Hypercholesterolaemia in Netherlands (IV)
  • 25 Oct 2010 Preclinical pharmacodynamics data in Hypercholesterolaemia released by Amsterdam Molecular Therapeutics
  • 20 May 2010 Preclinical trials in Hypercholesterolaemia in Netherlands (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top